Physician profile
David G Bains
NPI 1447419288
$5,166.85
in general payments reported to CMS, 2019-2025
32 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $229 · 2021: $459 · 2022: $821 · 2023: $790 · 2024: $947 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.42 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $755.59 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $533.69 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $426.92 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $384.48 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $359.28 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $345.84 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $312.88 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Opko Pharmaceuticals, LLC | $286.92 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $268.72 | 2022-2023 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $197.00 | 2019-2025 | |
| Ardelyx, INC. | $196.99 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.81 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $172.98 | 2022-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $111.15 | 2019-2025 | Auryxia, Vafseo |
| Ultragenyx Pharmaceutical INC. | $105.91 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $103.21 | 2021-2022 | |
| Lilly USA, LLC | $62.31 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $36.01 | 2025 | Empaveli |
| Mallinckrodt Enterprises LLC | $33.21 | 2019 | |
| Fresenius USA Marketing, INC. | $32.44 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $31.53 | 2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $31.11 | 2020-2021 | |
| Horizon Therapeutics Plc | $30.64 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $29.48 | 2024 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $27.94 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.87 | 2022 | |
| Cycle Pharmaceuticals INC | $18.15 | 2025 | Venxxiva |
| Cormedix INC. | $17.31 | 2025 | Defencath |
| Daiichi Sankyo INC. | $16.47 | 2022 | |
| Genentech USA, INC. | $15.73 | 2019 | |
| Medtronic, INC. | $11.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.